Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Ddb2em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Ddb2em1/Cya

Common Name
Ddb2-KO
Product ID
S-KO-20022
Backgroud
C57BL/6JCya
Strain ID
KOCMP-107986-Ddb2-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Ddb2-KO Mouse (Catalog S-KO-20022) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Ddb2-KO
Strain ID
KOCMP-107986-Ddb2-B6J-VB
Gene Name
Ddb2
Product ID
S-KO-20022
Gene Alias
2610043A19Rik
Background
C57BL/6JCya
Gene Full Name
damage specific DNA binding protein 2
Modification
Conventional knockout
NCBI ID
107986 (Mouse)
Phenotype
MGI:1355314
Chromosome
Chr 2 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000028696
NCBI Transcript ID
NM_028119
Target Region
Exon 5~7
Size of Effective Region
~1.7 kb
Overview of Gene Research
Ddb2, also known as damage-specific DNA-binding protein 2, is initially identified as a DNA damage recognition factor crucial for global genomic nucleotide excision repair (GG-NER) in human cells. It is also involved in multiple essential biological processes such as chromatin remodeling, gene transcription, cell cycle regulation, and protein decay [1].

In cancer research, Ddb2 shows diverse roles. In pancreatic ductal adenocarcinoma (PDAC), its reduced expression in cancer tissues correlates with shorter disease-free survival. Overexpression of Ddb2 in PDAC cells represses epithelial-to-mesenchymal transition (EMT), reduces cell migration and invasion, and sensitizes cells to chemotherapy drugs like 5-fluorouracil, oxaliplatin, and gemcitabine, suggesting its tumor-suppressive effects [2]. In breast and ovarian teratoma tissues, high Ddb2 levels are associated with lower CDT2 levels, and Ddb2 regulates DNA replication by degrading CDT2 [3]. In lung adenocarcinoma (LUAD), MBD2 binds to the methylated CpG DNA within the DDB2 promoter to repress DDB2 expression, promoting tumor metastasis [4]. In hepatocellular carcinoma cells, TRABID deubiquitinates DDB2 to promote cell proliferation [5].

In conclusion, Ddb2 plays essential roles in DNA repair, cell cycle regulation, and protein degradation. Its study in cancer models reveals its potential as a prognostic biomarker and therapeutic target in various cancers, especially in PDAC, where it may help predict chemotherapy response and prognosis. Understanding Ddb2's functions contributes to a deeper comprehension of cancer development mechanisms and may guide the development of new cancer therapies.

References:
1. Gilson, Pauline, Drouot, Guillaume, Witz, Andréa, Becuwe, Philippe, Harlé, Alexandre. 2019. Emerging Roles of DDB2 in Cancer. In International journal of molecular sciences, 20, . doi:10.3390/ijms20205168. https://pubmed.ncbi.nlm.nih.gov/31635251/
2. Dardare, Julie, Witz, Andréa, Betz, Margaux, Harlé, Alexandre, Gilson, Pauline. 2022. DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. In Frontiers in oncology, 12, 1052163. doi:10.3389/fonc.2022.1052163. https://pubmed.ncbi.nlm.nih.gov/36568213/
3. Wu, Xiaojun, Yu, Min, Zhang, Zhuxia, Xie, Ni, Lu, Fei. 2021. DDB2 regulates DNA replication through PCNA-independent degradation of CDT2. In Cell & bioscience, 11, 34. doi:10.1186/s13578-021-00540-5. https://pubmed.ncbi.nlm.nih.gov/33557942/
4. Zhang, Lei, Wang, Siyuan, Wu, Guo-Rao, Yong, Tuying, Wang, Cong-Yi. 2023. MBD2 facilitates tumor metastasis by mitigating DDB2 expression. In Cell death & disease, 14, 303. doi:10.1038/s41419-023-05804-1. https://pubmed.ncbi.nlm.nih.gov/37142578/
5. Chen, Yaping, Zhang, Xiaofei. 2022. TRABID targets DDB2 for deubiquitination to promote proliferation of hepatocellular carcinoma cells. In Biochemical and biophysical research communications, 625, 23-30. doi:10.1016/j.bbrc.2022.07.109. https://pubmed.ncbi.nlm.nih.gov/35944360/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research